Cyclerion Therapeutics Inc
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a sy… Read more
Cyclerion Therapeutics Inc (CYCN) - Net Assets
Latest net assets as of September 2025: $9.54 Million USD
Based on the latest financial reports, Cyclerion Therapeutics Inc (CYCN) has net assets worth $9.54 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.41 Million) and total liabilities ($877.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.54 Million |
| % of Total Assets | 91.58% |
| Annual Growth Rate | N/A |
| 5-Year Change | -85.12% |
| 10-Year Change | N/A |
| Growth Volatility | 28.49 |
Cyclerion Therapeutics Inc - Net Assets Trend (2016–2024)
This chart illustrates how Cyclerion Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cyclerion Therapeutics Inc (2016–2024)
The table below shows the annual net assets of Cyclerion Therapeutics Inc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $8.85 Million | -21.60% |
| 2023-12-31 | $11.29 Million | +8.00% |
| 2022-12-31 | $10.45 Million | -78.34% |
| 2021-12-31 | $48.25 Million | -18.90% |
| 2020-12-31 | $59.49 Million | -39.12% |
| 2019-12-31 | $97.73 Million | +1035.65% |
| 2018-12-31 | $-10.45 Million | -21.92% |
| 2017-12-31 | $-8.57 Million | -26.71% |
| 2016-12-31 | $-6.76 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cyclerion Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 26749200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $276.34 Million | 3122.51% |
| Total Equity | $8.85 Million | 100.00% |
Cyclerion Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Cyclerion Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tempest Security AB
ST:TSEC
|
$4.54 Million |
|
Reneuco Berhad
KLSE:7130
|
$4.55 Million |
|
Jet Freight Logistics Limited
NSE:JETFREIGHT
|
$4.55 Million |
|
CN Energy Group Inc
NASDAQ:CNEY
|
$4.55 Million |
|
Wave Entertainment Public Company Limited
BK:WAVE
|
$4.54 Million |
|
Mirae JSC
VN:KMR
|
$4.54 Million |
|
Verici Dx plc
PINK:VRCDF
|
$4.54 Million |
|
NSN Co. Ltd
KQ:031860
|
$4.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cyclerion Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 11,288,000 to 8,850,000, a change of -2,438,000 (-21.6%).
- Net loss of 3,057,000 reduced equity.
- Other comprehensive income increased equity by 12,000.
- Other factors increased equity by 607,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.06 Million | -34.54% |
| Other Comprehensive Income | $12.00K | +0.14% |
| Other Changes | $607.00K | +6.86% |
| Total Change | $- | -21.60% |
Book Value vs Market Value Analysis
This analysis compares Cyclerion Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.42x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-4.93 | $1.48 | x |
| 2017-12-31 | $-6.28 | $1.48 | x |
| 2018-12-31 | $-7.65 | $1.48 | x |
| 2019-12-31 | $71.39 | $1.48 | x |
| 2020-12-31 | $39.14 | $1.48 | x |
| 2021-12-31 | $24.65 | $1.48 | x |
| 2022-12-31 | $4.81 | $1.48 | x |
| 2023-12-31 | $4.83 | $1.48 | x |
| 2024-12-31 | $3.51 | $1.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cyclerion Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -34.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -152.85%
- • Asset Turnover: 0.21x
- • Equity Multiplier: 1.08x
- Recent ROE (-34.54%) is above the historical average (-96.29%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-62.88 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-93.07 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-114.21 Million |
| 2019 | -125.87% | -2729.27% | 0.02x | 1.91x | $-132.78 Million |
| 2020 | -130.78% | -3388.59% | 0.02x | 1.94x | $-83.75 Million |
| 2021 | -107.05% | -1555.63% | 0.06x | 1.23x | $-56.47 Million |
| 2022 | -421.72% | -14841.08% | 0.02x | 1.73x | $-45.12 Million |
| 2023 | -46.62% | 0.00% | 0.00x | 1.18x | $-6.39 Million |
| 2024 | -34.54% | -152.85% | 0.21x | 1.08x | $-3.94 Million |
Industry Comparison
This section compares Cyclerion Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cyclerion Therapeutics Inc (CYCN) | $9.54 Million | 0.00% | 0.09x | $4.54 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |